Distributor inventory | Tablet
Voglibose 0.3 mg
Type 2 diabetes mellitus (post‑prandial blood glucose control), used alone or as add‑on to other antidiabetic medicines along with diet and exercise
Voglibose is an alpha‑glucosidase inhibitor that delays the breakdown and absorption of carbohydrates in the small intestine. This reduces the rise in blood glucose after meals and improves post‑prandial glycaemic control.
Tablet; take exactly as prescribed, usually just before meals (or with the first bite of food). Swallow whole with water. Continue diet and exercise; do not stop or change dose without medical advice.
Common side effects of K-VOG 0.3MG TAB may include:
Not for type 1 diabetes or diabetic ketoacidosis. Use with caution in patients with intestinal obstruction, inflammatory bowel disease, colonic ulceration, malabsorption/chronic intestinal disorders. Monitor blood glucose and HbA1c regularly. When used with insulin or sulfonylureas, risk of hypoglycaemia increases—treat low sugar with glucose/dextrose (not sucrose). Use caution in liver disease; discontinue and seek care if severe abdominal symptoms occur.
